Liquid, aqueous pharmaceutical compositions of factor VII polypeptides
The present invention is directed to liquid, aqueous pharmaceutical compositions stabilised against chemical and/or physical degradation containing Factor VII polypeptides, and methods for preparing and using such compositions, as well as vials containing such compositions, and the use of such compositions in the treatment of a Factor VII-responsive syndrome. The main embodiment is represented by a liquid, aqueous pharmaceutical composition comprising at least 0.01 mg/mL of a Factor VII polypeptide (i); a buffering agent (ii) suitable for keeping pH in the range of from about 4.0 to about 9.0; and at least one stabilising agent (iii) comprising a —C(═N—Z 1 —R 1 )—NH—Z 2 —R 2 motif, e.g. benzamidine compounds and guanidine compounds such as arginine.
1. A method for treating a Factor VII-responsive syndrome comprising administering to a subject in need thereof an effective amount of a liquid, aqueous, and pharmaceutically acceptable composition, the composition comprising
(i) at least 0.01 mg/mL of a Factor VII polypeptide that exhibits substantially the same or improved biological activity as compared to wild type Factor VII;
(ii) a buffering agent suitable for keeping pH of the composition in the range of about 4 to about 9; and
(iii) a stabilizing composition comprising a benzamidine compound according to the formula —C 6 H 4 —C(═N—Z 1 —R 1 )—NH—Z 2 —R 2 , wherein
(a) C 6 H 4 denotes a substituted benzene ring, and
(b) Z 1 and Z 2 independently are selected from the group consisting of —O—, —S—, —NR H− and a single bond, where R H is selected from the group consisting of hydrogen, C 1-4 -alkyl, aryl and arylmethyl, and R 1 and R 2 independently are selected from the group consisting of hydrogen, optionally substituted C 1-6 -alkyl, optionally substituted C 2-6 -alkenyl, optionally substituted aryl, optionally substituted heterocyclyl, wherein
—C═N—Z 1 —R 1 optionally forms part of a heterocyclic ring,
—C—NH—Z 2 —R 2 optionally forms part of a heterocyclic ring, or
—C(═N—Z 1 —R 1 )—NH-Z 2 —R 2 optionally forms a heterocyclic ring wherein Z 1 —R 1 —R 2 —Z 2 — is a biradical.
2. The method of claim 1 , wherein the Factor VII-responsive syndrome is a bleeding disorder.
3. The method of claim 1 , wherein the Factor VII-responsive syndrome is a disorder caused by a clotting factor deficiency.
4. The method of claim 1 , wherein the Factor VII-responsive syndrome is haemophilia A.
5. The method of claim 1 , wherein the Factor VII-responsive syndrome is haemophilia B.
6. The method of claim 1 , wherein the Factor VII-responsive syndrome is a disorder caused by Factor VII deficiency.
7. The method of claim 1 , wherein the Factor VII-responsive syndrome is thrombocytopenia.
8. The method of claim 1 , wherein the Factor VII-responsive syndrome is von Willebrand's disease.
9. The method of claim 1 , wherein the Factor VII-responsive syndrome is a disorder caused by a clotting factor inhibitor.